1 Cash-Producing Stock with Exciting Potential and 2 We Ignore

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Cash flow is valuable, but it’s not everything - StockStory helps you identify the companies that truly put it to work. That said, here is one cash-producing company that excels at turning cash into shareholder value and two that may struggle to keep up.

Two Stocks to Sell:

Live Nation (LYV)

Trailing 12-Month Free Cash Flow Margin: 6.6%

Owner of Ticketmaster and operator of music festival EDC, Live Nation (NYSE:LYV) is a company specializing in live event promotion, venue management, and ticketing services for concerts and shows.

Why Does LYV Fall Short?

1. Annual sales growth of 5.3% over the last two years lagged behind its consumer discretionary peers as its large revenue base made it difficult to generate incremental demand
2. Subpar operating margin of 4.3% constrains its ability to invest in process improvements or effectively respond to new competitive threats
3. Capital intensity will likely ramp up in the next year as its free cash flow margin is expected to contract by 1.1 percentage points

Live Nation is trading at $156.91 per share, or 122.4x forward P/E. Dive into our free research report to see why there are better opportunities than LYV.

GoodRx (GDRX)

Trailing 12-Month Free Cash Flow Margin: 20.6%

Started in 2011 to tackle the problem of high prescription drug costs in America, GoodRx (NASDAQ:GDRX) operates a digital platform that helps consumers find lower prices on prescription medications through price comparison tools and discount codes.

Why Should You Sell GDRX?

1. Muted 2.4% annual revenue growth over the last two years shows its demand lagged behind its healthcare peers
2. Smaller revenue base of $796.9 million means it hasn’t achieved the economies of scale that some industry juggernauts enjoy
3. Negative returns on capital show that some of its growth strategies have backfired

At $2.29 per share, GoodRx trades at 7.3x forward P/E. To fully understand why you should be careful with GDRX, check out our full research report (it’s free).

One Stock to Watch:

Ollie's (OLLI)

Trailing 12-Month Free Cash Flow Margin: 7.3%

Often located in suburban or semi-rural shopping centers, Ollie’s Bargain Outlet (NASDAQ:OLLI) is a discount retailer that acquires excess inventory then sells at meaningful discounts.

Why Are We Positive On OLLI?

1. Rapid rollout of new stores to capitalize on market opportunities makes sense given its strong same-store sales performance
2. Comparable store sales rose by 3.2% on average over the past two years, demonstrating its ability to drive increased spending at existing locations
3. Expected revenue growth of 13.4% for the next year suggests its market share will rise

Ollie’s stock price of $94.81 implies a valuation ratio of 21.1x forward P/E. Is now a good time to buy? See for yourself in our comprehensive research report, it’s free.

High-Quality Stocks for All Market Conditions

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.